AI stock analysis · Biotechnology · Last analyzed Aug 20, 2026
Compass Score
3.0/5
Call
Hold
Price
$2.23
AI Target
$9.00 +303.6%
AI Analyst Summary
Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR-T cell therapies (off-the-shelf, donor-derived) targeting blood cancers, with its lead programs in relapsed/refractory B-cell malignancies representing a multi-billion dollar addressable market if pivotal data succeeds. Analyst sentiment is overwhelmingly bullish — 11 of 12 analysts rate the stock a Buy with a consensus target of $9.00, implying over 300% upside from current levels, reflecting strong conviction in the pipeline's differentiation. The primary risk is binary clinical trial outcomes; failure in any key Phase 2/3 readout could be catastrophic for a company with no commercial revenue and ongoing cash burn.
Catalysts
Pivotal clinical data readouts for lead allogeneic CAR-T candidates (e.g., cemacabtagene ansegedleucel) in relapsed/refractory B-cell NHL, which could serve as a de-risking event and re-rating trigger.
Potential partnership or licensing deal with a large biopharma leveraging the allogeneic platform, which would validate the technology and provide non-dilutive capital to extend the cash runway.
FDA regulatory interactions or IND clearances for next-generation pipeline programs that could expand the addressable indication set and support a broader pipeline valuation narrative.
Fundamentals
PeN/A (loss-making) · 1.0/5
No trailing P/E available; company is pre-revenue/loss-making with a negative forward P/E of -3.2x, indicating no current earnings base. Typical of early-stage clinical-stage biotech.
PegN/A · 3.0/5
PEG ratio is unavailable due to negative earnings. Scored neutral per guidelines for missing PEG in loss-making biotech context.
Analyst RatingStrong Buy consensus (1.4) · 5.0/5
Analyst consensus of 1.4 reflects near-unanimous bullish sentiment with 11 Buy ratings and 1 Hold. Well above the 5-analyst threshold, mapping to a top-tier score of 5.
No earnings or revenue growth data available; company is clinical-stage with no commercial products. Losses are expected but there is no improving trend to score positively. Scored below average given persistent losses and no revenue catalyst yet.
Price Target Beat3 of 4 quarters beat · 2.0/5
EPS beat rate of 3 of 4 quarters available is a partial positive, but only 4 quarters of data are provided. Scored 2 per guidelines mapping 3-of-8 equivalent context; insufficient full history caps confidence.
Management earns a neutral-to-constructive score. Strong analyst conviction (11 of 12 bullish) suggests credibility in pipeline strategy, but limited EPS beat history and ongoing cash burn in clinical-stage operations prevent a higher score.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.